Advocacy Recruiting for Huntington’s Disease Clinical Trials
LaVonne Goodman(Huntington's Disease Association), Pinky Agarwal, Andrew McGarry(Cooper Medical School of Rowan University), Cherrie Sia, Karl Kieburtz(Rochester Institute of Technology), Louise Vetter, Charles S. Venuto(University of Rochester), Roger Carnes, Fred Taubman
Cited by 8
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
|Neurology|2016|137
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
|The Lancet Neurology|2023|128
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
|The Lancet Neurology|2018|108
Pharmacologic approaches to the treatment of Huntington's disease
|Movement Disorders|2011|84